Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Treatment Options for Advanced Stage Relapsed Endometrial Carcinoma

March 10th 2022

Physician-researchers discuss the risk of recurrence in endometrial carcinoma and the available treatment options after relapse.

Biomarker Testing in Endometrial Carcinoma

March 4th 2022

An overview of biomarker testing in endometrial carcinoma.

Endometrial Carcinoma: Clinical Scenario 1

March 4th 2022

Oncologists describe a typical presentation of endometrial carcinoma and debate the implications of radiation treatment.

Paclitaxel/Carboplatin Noninferior to Paclitaxel/Ifosfamide in Uterine Carcinosarcoma

March 2nd 2022

The addition of carboplatin to paclitaxel prolonged overall survival and progression-free survival, and proved to be noninferior to the standard combination of paclitaxel and ifosfamide in patients with uterine carcinosarcoma.

Institutional Perspectives in Cancer- Women’s Health: Chaired by Alexander Olawaiye, MD

February 23rd 2022

Bob the Builder: Robert C. Young Is Giant of Cancer Care in Gynecologic Cancer

February 21st 2022

"If you stay at home too long, with too narrow a focus, you lose sight of what’s happening in the world."

Dr. Brown on the Benefits of Minimally Invasive Surgery in Ovarian Cancer

February 17th 2022

Jubilee Brown, MD, discusses the benefits of minimally invasive surgery in ovarian cancer.

Objectively Accurate Interpretation of Clinical Trials Results Poses a Challenge

February 15th 2022

Much has been written regarding the essential role of clinical trials in the major advances in cancer therapy and observed improvement in disease-related morbidity and mortality.

Frontline Selinexor Maintenance Improves PFS in Advanced or Recurrent Endometrial Cancer

February 8th 2022

Frontline maintenance treatment with selinexor resulted in a statistically significant improvement in median progression-free survival vs placebo in patients with advanced or recurrent endometrial cancer, meeting the primary end point of the phase 3 SIENDO trial.

Virtual Surveillance Visits with Symptom, Serum CA-125 Review May Offer Alternative for Ovarian Cancer Recurrence Detection.

February 1st 2022

In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.

Dr. Olawaiye on Investigating Balstilimab Plus Zalifrelimab in Gynecologic Cancers

February 1st 2022

Alexander Babatunde Olawaiye, MD, discusses the investigation of balstilimab plus zalifrelimab in gynecologic cancers.

Immunotherapy Approvals Signal a Need for Molecular Testing in Endometrial Cancer

January 31st 2022

Sarah Lee, MD, MBA, discusses the use of checkpoint inhibitors in endometrial cancer, research regarding the association between MSI-H, dMMR, and TMB-H disease, and the importance of broad molecular testing to ensure all eligible patients are appropriately matched to immunotherapeutic options.

Increasing Rate of High-Risk Endometrial Cancer in Black Women Prompts Questions Into Underlying Causes

January 30th 2022

Cortney Eakin, MD, discusses alarming trends in uterine cancer histologies in Black women and some of the potential underlying risk factors at play.

Cemiplimab sBLA in Second-Line Advanced Cervical Cancer Voluntarily Withdrawn

January 29th 2022

Regeneron Pharmaceuticals, Inc. and Sanofi announced the voluntarily withdrawal of the supplemental biologics license application for cemiplimab-rwlc as a second-line treatment for patients with advanced cervical cancer whose disease progressed on or after chemotherapy.

Dr. Lee on the Association of MSI-H, dMMR, and TMB-H Features in Endometrial Cancer

January 28th 2022

Sarah Lee, MD, MBA, discusses the association of microsatellite instability–high, mismatch repair deficiency, and tumor mutational burden–high features in endometrial cancer.

Dr. Karam on the Role of Debulking Surgery in Recurrent Ovarian Cancer

January 28th 2022

Amer Karam, MD, discusses determining whether to use debulking surgery after recurrence in ovarian cancer.

Dr. Casablanca on the Integration of Pembrolizumab in Recurrent or Metastatic Cervical Cancer

January 28th 2022

Yovanni Casablanca, MD, discusses the integration of pembrolizumab (Keytruda) into the paradigm of recurrent or metastatic cervical cancer.

Immunotherapy Shakes Up Cervical Cancer Treatment Paradigm

January 28th 2022

Yovanni Casablanca, MD, discusses the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.

Cervical Cancer Treatment Paradigm Is Bolstered With Newly Approved Therapies

January 28th 2022

Treatment of patients with metastatic cervical cancer remains challenging—the 5-year overall survival rate is just 17%.

Active Clinical Trials of Interest in Endometrial Cancer Explore Novel Up-Front Approaches

January 27th 2022

Bradley R. Corr, MD, discusses practice-changing developments and active clinical trials that are being done in endometrial cancer.